New treatment develops a pharmaceutical laboratory for accelerated evolutionary biotechnology under the guidance of Dr. Sc. Ilan Morad, according to the report.
"We believe we will offer a full cancer drug for a year"He said Dan Aridor, president of the company. "Our cancer drug will be effective from the first day, it will take several weeks and will have minimal side effects or nothing at much lower cost than most other treatments on the market".
Treatment, called "MuTaTo", will use a combination of cancer and toxin peptides that will specifically kill cancer cells.
Treatment will eventually be personalized and patients will be given a specific cocktail of drugs by type of cancer, Morad said.
Despite the importance of the announcement, some voices call into question the operation of the new treatment, given that, for example, it is only tested on mice.
In that sense, the deputy medical director of the American Cancer Society's National Office, Len Lichtenfeldsaid in the blog blog da "It is understood that we all share the hope that they are accurate".
"Unfortunately, we need to be aware that this is far from being effective treatment for people with cancer, let alone cure", He said.
Finally, the expert noted that Israeli researchers did not publicly display collected data to support his announcement, unless they found evidence that the treatment was successful in mice, stating that they had all the time interviewed with local media, published on page publimetro.cl.